The aminoglycoside-modifying enzyme Eis2 represents a new potential in vivo target for reducing antimicrobial drug resistance in Mycobacterium abscessus complex. Issue 6 (1st December 2022)

• Record Type: Journal Article
• Authors: Lorè, Nicola Ivan; Saliu, Fabio; Spitaleri, Andrea; Schäfle, Daniel; Nicola, Francesca; Cirillo, Daniela Maria; Sander, Peter
• Is Part Of: European respiratory journal. Volume 60:Issue 6(2022)
• Publication Date: 2022-12-01
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01541-2022
• Languages: English
• ISSNs: 0903-1936

Abstract

Mycobacterium abscessus complex (MABSC) is an emerging opportunistic pathogen complex responsible for lung infections after lung colonisation in people with pulmonary disorders, such as bronchiectasis or cystic fibrosis [1, 2]. It is becoming one of the most clinically relevant nontuberculous mycobacteria because of the severity of infection and poor response to antibiotic treatment. The MABSC includes three subspecies: M. abscessus abscessus, bolletii and massiliense [3–5]. MABSC pulmonary disease is characterised by the presence of specific microbiological, clinical and radiological features described in the ATS/ERS/ESCMID/ IDSA (American Thoracic Society/European Respiratory Society/European Society of Clinical Microbiology and Infectious Diseases/Infectious Diseases Society of America) consensus statement [1]. This study identified innovative therapeutic targets to reinforce existing current antibiotic treatments against M. abscessus complex, exploiting a murine preclinical model of respiratory infection and 727 publicly available genomes from clinical isolates https://bit.ly/3eD4Pja